Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice

Bibliography

• Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011;13:703-10
   PubMed Web of Science ®Google Scholar
• Yoon NM, Cavaghan MK, Brunelle RL, et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic Endocrinology outpatient setting. Clin Therap 2009;31:1511-23
   PubMed Web of Science ®Google Scholar
• Nayak UA, Govindan J, Baskar V, et al. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687-94
   PubMed Web of Science ®Google Scholar
• Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285-92
   PubMedGoogle Scholar
• Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012;35:955-8
   PubMed Web of Science ®Google Scholar
• Levin PA, Mersey JH, Zhou S, et al. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract 2012;18:17-25
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
   PubMed Web of Science ®Google Scholar
• Samson SL, Garber A. GLP1-R agonist therapy for diabetes: benefits and potential risks. Curr Opin Endocrinol Diabetes Obes 2013;20:87-97
   PubMed Web of Science ®Google Scholar
• Holst JJ, Vilsbøll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013;15:3-14
   PubMed Web of Science ®Google Scholar
• Tzefos M, Olin JL. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 Diabetes Mellitus. The Annals of Pharmacotherapy 2010;44:1294-300
   PubMed Web of Science ®Google Scholar
• Anholm C, Frandsen H, Højgaard-Hansen EC, et al. Use of once daily liraglutide in type 2 diabetes: clinical practice and experiences from combination with oral antidiabetic drugs or insulin. Diabetes 2011;60:A314
   Web of Science ®Google Scholar
• Ryder REJ, Thong KY, Cull ML, Mills AP, Walton C. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetologia 2011;54(Suppl 1):S326
   Google Scholar
• Lind M, Jendle J, Torffvit O, et al. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. Prim Care Diabetes 2012;6:41-6
   PubMed Web of Science ®Google Scholar
• Aronson R. Glucagon-like peptide (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycaemia and high treatment satisfaction. Expert Rev Clin Pharmacol 2013;6:603-12
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily Lixisenatide for type 2 diabetes inadequately controlled by established basal insulin. A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-96
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, et al. Adding once-daily Lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine. A 24-week, randomized, placebo-controlled study (GetGoal-Duo1). Diabetes Care 2013;36:2497-503
   PubMed Web of Science ®Google Scholar
• Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910-17
   PubMed Web of Science ®Google Scholar
• Balena R, Hensley IE, Miller S, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013;15:485-502
   PubMed Web of Science ®Google Scholar
• Berlie H, Hurren KM, Pinelli NR. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes Metabolic Syndr Obes 2012;5:165-74
   PubMedGoogle Scholar
• Jendle J, Martin SA, Milicevic Z. Insulin and GLP-1 analogue combinations in type 2 diabetes mellitus: a critical review. Expert Opin Investig Drugs 2012;21:1463-74
   PubMed Web of Science ®Google Scholar
• Tobin GS, Cavaghan MK, Hoogwerf BJ, et al. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract 2012;66:1147-57
   PubMed Web of Science ®Google Scholar
• Morrow L, Hompesch M, Guthrie H, et al. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamics effects with no pharmacokinetic interaction. Diabetes Obes Metab 2011;13:75-80
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin. Diabetes Care 2010;33:1509-15
   PubMed Web of Science ®Google Scholar
• Viswanathan P, Chaudhuri A, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444-50
   PubMedGoogle Scholar
• Phillips S, Gulbranson N, Kabadi U, et al. Marked improvement in glycemic control with exenatide (Byetta®) on addition to metformin, sulfonylurea and insulin glargine in type 2 diabetes mellitus. Diabetes 2011;60:A614
   PubMed Web of Science ®Google Scholar
• Rachabattula H, Mukhtar RYA, Taylor PN, Robinson AM. Exenatide and insulin combination therapy in type 2 diabetes. Diabetes 2011;60:A606
   Google Scholar
• Pawaskar M, Li Q, Lee LJ, Reynolds M, Hoogwerf BJ. Clinical effectiveness of concomitant therapy with exenatide BID and basal insulin in patients with type 2 diabetes: a real-world analysis. World Diabetes Congress. Dubai, United Arab Emirates: International Diabetes Federation 2011
   Google Scholar
• Christofides EA, Boyle PJ, Johnson MT, Robinson AM. Real world clinical experience with exenatide, a long term study on weight and A1C control. Diabetes 2009;58:A154
   Web of Science ®Google Scholar
• Houser D, Christofides E. Real world clinical experience with exenatide, a long term study on weight and A1c control. Diabetes 2011;60:A618
   Web of Science ®Google Scholar
• Vithian K, Qureshi A, Chen B, Steer K. Exenatide replacing insulin in obese/overweight patients with type 2 diabetes; a district general hospital experience. Diabetic Medicine. Diabetes 2009;24:139-40
   Google Scholar
• Riddle M, Ahmann A, Basu A, Aroda V, Ratner R. Metformin + exenatide + basal insuiln vs metformin + placebo + basal insulin: reaching A1c <6.5% without weight-gain or serious hypoglycemia. Diabetes 2010;59
   Google Scholar